Acromegaly is one of those diseases that immediately caught our attention when we first heard about it in medical school. We stared at the textbook pictures of big hands and coarse faces—maybe a very ...

Clinicians who treat patients with acromegaly commonly show a lack of awareness of the severity and pattern of patient symptoms that can occur even when treatment suggests the condition is under ...

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly are more likely to have hypertension, diabetes and other comorbidities than healthy ...

Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

Conditions that affect the pituitary gland include acromegaly and gigantism, Cushing and empty sella syndromes, prolactinoma, and more. Noncancerous tumors most often cause conditions that affect your ...

Gigantism and acromegaly are similar, but they also have notable differences. For starters, gigantism occurs in children. The overproduction of growth hormone occurs during puberty, when a child is ...

Gigantism and acromegaly are growth disorders that result from excess amounts of growth hormone in the body. The conditions are similar but have several differences. Growth hormone is one of the ...

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...

Pituitary gland disorders occur when the pituitary gland produces too little or too much of certain hormones. Some examples are Cushing’s disease, empty sella syndrome, and acromegaly. Pituitary gland ...

What Is Palsonify, and Why Does It Matter? Palsonify (paltusotine) is a new once-daily oral medicine approved to treat adults with acromegaly who either didn’t get much help from surgery or cannot ...

Mycapssa is an oral somatostatin analogue. Mycapssa® (octreotide delayed-release capsules; Chiasma) is now available for the long-term maintenance treatment of adult patients with acromegaly who have ...

After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...